Bipolar disorders

The Lancet

Volumn 396, Issue 10265, 2020, Pages 1841-1856

  McIntyre, Roger S ^a,b,c,d   Berk, Michael ^e,f,g,h,i   Brietzke, Elisa ^j,k,l   Goldstein, Benjamin I ^b,m   López Jaramillo, Carlos ^n,o   Kessing, Lars Vedel ^p,q   Malhi, Gin S ^s,t   Nierenberg, Andrew A ^b   Rosenblat, Joshua D ^a,b,u   Majeed, Amna ^a   Vieta, Eduard ^v   Vinberg, Maj ^q,r   Young, Allan H ^w   Mansur, Rodrigo B ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d BRAIN AND COGNITION DISCOVERY FOUNDATION   (Canada)

^e DEAKIN UNIVERSITY   (Australia)

^f BARWON HEALTH   (Australia)

^g THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^h FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j KINGSTON GENERAL HOSPITAL   (Canada)

^k QUEEN S UNIVERSITY   (Canada)

^l QUEEN S UNIVERSITY   (Canada)

^m SUNNYBROOK RESEARCH INSTITUTE   (Canada)

ⁿ UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^o HOSPITAL UNIVERSITARIO SAN VICENTE FUNDACIÓN   (Colombia)

^p Rigshospitalet   (Denmark)

^q UNIVERSITY OF COPENHAGEN   (Denmark)

^r Psychiatric Centre North Zealand   (Denmark)

^s UNIVERSITY OF SYDNEY   (Australia)

^t CIBERSAM ^*  (Australia)

^u HARVARD MEDICAL SCHOOL   (United States)

^v UNIVERSITY OF BARCELONA   (Spain)

^w BETHLEM ROYAL HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; BREXANOLONE; CARBAMAZEPINE; CARIPRAZINE; FLUOXETINE PLUS OLANZAPINE; HALOPERIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; INFLIXIMAB; INSULIN; KETAMINE; LAMOTRIGINE; LITHIUM SALT; LUMATEPERONE; LURASIDONE; MINOCYCLINE; NEUROLEPTIC AGENT; NITROUS OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; PALIPERIDONE; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; PROLACTIN; QUETIAPINE; RISPERIDONE; UBIDECARENONE; VALPROATE SEMISODIUM; ZIPRASIDONE; ANTICONVULSIVE AGENT; LITHIUM; TRANQUILIZER; VALPROIC ACID;

AKATHISIA; ANTIDEPRESSANT ACTIVITY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; BODY WEIGHT GAIN; CARDIOVASCULAR DISEASE; CELL METABOLISM; CHILD ABUSE; COGNITIVE BEHAVIORAL THERAPY; COGNITIVE DEFECT; COMORBIDITY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; GENETIC ASSOCIATION; GENETIC RISK; HERITABILITY; HUMAN; HYPOMANIA; HYPOTHYROIDISM; INFLAMMATION; LIFESTYLE MODIFICATION; LIVER TOXICITY; MAINTENANCE THERAPY; MAJOR DEPRESSION; MENSTRUAL IRREGULARITY; METABOLIC DISORDER; MONOAMINERGIC SYSTEM; MORBIDITY; MORTALITY; NEPHROTOXICITY; NERVE CELL PLASTICITY; OVARY POLYCYSTIC DISEASE; PANCREATITIS; PATHOGENESIS; PHOTOTHERAPY; POLYURIA; POSTNATAL DEPRESSION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOEDUCATION; PSYCHOSOCIAL CARE; QT PROLONGATION; RASH; REPEATED DRUG DOSE; REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION; REVIEW; SCHIZOPHRENIA; SCREENING; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUICIDAL BEHAVIOR; SUICIDE; TARDIVE DYSKINESIA; TERATOGENICITY; TREMOR; ADOLESCENT; ADULT; ADVERSE EVENT; CHILD; CLASSIFICATION; COMPLICATION; ENVIRONMENTAL EXPOSURE; GENETICS; MANIA; PSYCHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CARBAMAZEPINE; CARDIOVASCULAR DISEASES; CHILD; CHILD ABUSE; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; ENVIRONMENTAL EXPOSURE; HUMANS; LAMOTRIGINE; LITHIUM; MANIA; SUICIDE; VALPROIC ACID; YOUNG ADULT;

EID: 85096930425     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(20)31544-0     Document Type: Review

References (197)

1. Merikangas, KR, Jin, R, He, JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 68 (2011), 241–251.
2. Steel, Z, Marnane, C, Iranpour, C, et al. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. Int J Epidemiol 43 (2014), 476–493.
3. Godman, B, Grobler, C, Van-De-Lisle, M, et al. Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries. Expert Opin Pharmacother 20 (2019), 2237–2255.
4. Sentissi, O, Popovic, D, Moeglin, C, et al. Predominant polarity in bipolar disorder patients: the COPE bipolar sample. J Affect Disord 250 (2019), 43–50.
5. Nowrouzi, B, McIntyre, RS, MacQueen, G, et al. Admixture analysis of age at onset in first episode bipolar disorder. J Affect Disord 201 (2016), 88–94.
6. Moreno, C, Laje, G, Blanco, C, Jiang, H, Schmidt, AB, Olfson, M, National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry 64 (2007), 1032–1039.
7. Jamison, KR, Great wits and madness: more near allied?. Br J Psychiatry 199 (2011), 351–352.
8. Cloutier, M, Greene, M, Guerin, A, Touya, M, Wu, E, The economic burden of bipolar I disorder in the United States in 2015. J Affect Disord 226 (2018), 45–51.
9. Kleine-Budde, K, Touil, E, Moock, J, Bramesfeld, A, Kawohl, W, Rössler, W, Cost of illness for bipolar disorder: a systematic review of the economic burden. Bipolar Disord 16 (2014), 337–353.
10. Jin, H, McCrone, P, Cost-of-illness studies for bipolar disorder: systematic review of international studies. Pharmacoeconomics 33 (2015), 341–353.
11. Laursen, TM, Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res 131 (2011), 101–104.
12. Osby, U, Brandt, L, Correia, N, Ekbom, A, Sparén, P, Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 58 (2001), 844–850.
13. Kessing, LV, Vradi, E, Andersen, PK, Life expectancy in bipolar disorder. Bipolar Disord 17 (2015), 543–548.
14. Hayes, JF, Marston, L, Walters, K, King, MB, Osborn, DPJ, Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000-2014. Br J Psychiatry 211 (2017), 175–181.
15. Staudt Hansen, P, Frahm Laursen, M, Grøntved, S, Puggard Vogt Straszek, S, Licht, RW, Nielsen, RE, Increasing mortality gap for patients diagnosed with bipolar disorder—a nationwide study with 20 years of follow-up. Bipolar Disord 21 (2019), 270–275.
16. Lomholt, LH, Andersen, DV, Sejrsgaard-Jacobsen, C, et al. Mortality rate trends in patients diagnosed with schizophrenia or bipolar disorder: a nationwide study with 20 years of follow-up. Int J Bipolar Disord, 7, 2019, 6.
17. Kessing, LV, Vradi, E, McIntyre, RS, Andersen, PK, Causes of decreased life expectancy over the life span in bipolar disorder. J Affect Disord 180 (2015), 142–147.
18. Hällgren, J, Ösby, U, Westman, J, Gissler, M, Mortality trends in external causes of death in people with mental health disorders in Sweden, 1987–2010. Scand J Public Health 47 (2019), 121–126.
19. Dong, M, Lu, L, Zhang, L, et al. Prevalence of suicide attempts in bipolar disorder: a systematic review and meta-analysis of observational studies. Epidemiol Psychiatr Sci, 29, 2019, e63.
20. Tietbohl-Santos, B, Chiamenti, P, Librenza-Garcia, D, et al. Risk factors for suicidality in patients with panic disorder: a systematic review and meta-analysis. Neurosci Biobehav Rev 105 (2019), 34–38.
21. Plans, L, Barrot, C, Nieto, E, et al. Association between completed suicide and bipolar disorder: a systematic review of the literature. J Affect Disord 242 (2019), 111–122.
22. Malhi, GS, Irwin, L, Hamilton, A, et al. Modelling mood disorders: an ACE solution?. Bipolar Disord 20:suppl 2 (2018), 4–16.
23. Tondo, L, Vázquez, GH, Pinna, M, Vaccotto, PA, Baldessarini, RJ, Characteristics of depressive and bipolar disorder patients with mixed features. Acta Psychiatr Scand 138 (2018), 243–252.
24. McIntyre, RS, Mixed features and mixed states in psychiatry: from calculus to geometry. CNS Spectr 22 (2017), 116–117.
25. Shim, IH, Bae, DS, Bahk, W-M, Anxiety or agitation in mood disorder with mixed features: a review with a focus on validity as a dimensional criterion. Ann Clin Psychiatry 28 (2016), 213–220.
26. Perugi, G, Angst, J, Azorin, JM, et al. Mixed features in patients with a major depressive episode: the BRIDGE-II-MIX study. J Clin Psychiatry 76 (2015), e351–e358.
27. Malhi, GS, Das, P, Gessler, D, Outhred, T, Fritz, K, The mixed features of DSM-5. Aust N Z J Psychiatry 49 (2015), 842–843.
28. Malhi, GS, Fritz, K, Allwang, C, et al. Agitation for recognition by DSM-5 mixed features specifier signals fatigue?. Aust N Z J Psychiatry 49 (2015), 499–501.
29. Brancati, GE, Vieta, E, Azorin, JM, et al. The role of overlapping excitatory symptoms in major depression: are they relevant for the diagnosis of mixed state?. J Psychiatr Res 115 (2019), 151–157.
30. Perugi, G, Pacchiarotti, I, Mainardi, C, et al. Patterns of response to antidepressants in major depressive disorder: drug resistance or worsening of depression are associated with a bipolar diathesis. Eur Neuropsychopharmacol 29 (2019), 825–834.
31. Malhi, GS, Fritz, K, Elangovan, P, Irwin, L, Mixed states: modelling and management. CNS Drugs 33 (2019), 301–313.
32. McIntyre, RS, Calabrese, JR, Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. Curr Med Res Opin 35 (2019), 1993–2005.
33. Messer, T, Lammers, G, Müller-Siecheneder, F, Schmidt, R-F, Latifi, S, Substance abuse in patients with bipolar disorder: a systematic review and meta-analysis. Psychiatry Res 253 (2017), 338–350.
34. Cawkwell, PB, Bolton, KW, Karmacharya, R, Öngür, D, Shinn, AK, Two-year diagnostic stability in a real-world sample of individuals with early psychosis. Early Interv Psychiatry, 2020 published online Feb 10. https://doi.org/10.1111/eip.12930.
35. Fiedorowicz, JG, Endicott, J, Leon, AC, Solomon, DA, Keller, MB, Coryell, WH, Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry 168 (2011), 40–48.
36. Perugi, G, Angst, J, Azorin, JM, et al. Relationships between mixed features and borderline personality disorder in 2811 patients with major depressive episode. Acta Psychiatr Scand 133 (2016), 133–143.
37. Dagani, J, Signorini, G, Nielssen, O, et al. Meta-analysis of the interval between the onset and management of bipolar disorder. Can J Psychiatry 62 (2017), 247–258.
38. Angst, J, Sellaro, R, Stassen, HH, Gamma, A, Diagnostic conversion from depression to bipolar disorders: results of a long-term prospective study of hospital admissions. J Affect Disord 84 (2005), 149–157.
39. Kessing, LV, Willer, I, Andersen, PK, Bukh, JD, Rate and predictors of conversion from unipolar to bipolar disorder: a systematic review and meta-analysis. Bipolar Disord 19 (2017), 324–335.
40. Ratheesh, A, Davey, C, Hetrick, S, et al. A systematic review and meta-analysis of prospective transition from major depression to bipolar disorder. Acta Psychiatr Scand 135 (2017), 273–284.
41. Li, C-T, Bai, YM, Huang, YL, et al. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. Br J Psychiatry 200 (2012), 45–51.
42. Hirschfeld, RMA, Lewis, L, Vornik, LA, Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 64 (2003), 161–174.
43. Youngstrom, EA, Egerton, GA, Genzlinger, J, Freeman, LK, Rizvi, SH, Van Meter, A, Improving the global identification of bipolar spectrum disorders: meta-analysis of the diagnostic accuracy of checklists. Psychol Bull 144 (2018), 315–342.
44. Wang, Y-Y, Xu, DD, Liu, R, et al. Comparison of the screening ability between the 32-item Hypomania Checklist (HCL-32) and the Mood Disorder Questionnaire (MDQ) for bipolar disorder: a meta-analysis and systematic review. Psychiatry Res 273 (2019), 461–466.
45. Merikangas, KR, Akiskal, HS, Angst, J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 64 (2007), 543–552.
46. Sylvia, LG, Shelton, RC, Kemp, DE, et al. Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE). Bipolar Disord 17 (2015), 212–223.
47. McIntyre, RS, Konarski, JZ, Yatham, LN, Comorbidity in bipolar disorder: a framework for rational treatment selection. Hum Psychopharmacol 19 (2004), 369–386.
48. Vaccarino, SR, Rajji, TK, Gildengers, AG, et al. Allostatic load but not medical burden predicts memory performance in late-life bipolar disorder. Int J Geriatr Psychiatry 33 (2018), 546–552.
49. Kapczinski, NS, Mwangi, B, Cassidy, RM, et al. Neuroprogression and illness trajectories in bipolar disorder. Expert Rev Neurother 17 (2017), 277–285.
50. Yapici Eser, H, Kacar, AS, Kilciksiz, CM, Yalçinay-Inan, M, Ongur, D, Prevalence and associated features of anxiety disorder comorbidity in bipolar disorder: a meta-analysis and meta-regression study. Front Psychiatry, 9, 2018, 229.
51. Onyeka, IN, Collier Høegh, M, Nåheim Eien, EM, Nwaru, BI, Melle, I, Comorbidity of physical disorders among patients with severe mental illness with and without substance use disorders: a systematic review and meta-analysis. J Dual Diagn 15 (2019), 192–206.
52. McElroy, SL, Winham, SJ, Cuellar-Barboza, AB, et al. Bipolar disorder with binge eating behavior: a genome-wide association study implicates PRR5-ARHGAP8. Transl Psychiatry, 8, 2018, 40.
53. McIntyre, RS, Correll, C, Predicting and preventing bipolar disorder: the need to fundamentally advance the strategic approach. Bipolar Disord 16 (2014), 451–454.
54. Coello, K, Kjærstad, HL, Stanislaus, S, et al. Thirty-year cardiovascular risk score in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. Aust N Z J Psychiatry 53 (2019), 651–662.
55. Goldstein, BI, Carnethon, MR, Matthews, KA, et al. Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: a scientific statement from the American Heart Association. Circulation 132 (2015), 965–986.
56. Petri, E, Bacci, O, Barbuti, M, et al. Obesity in patients with major depression is related to bipolarity and mixed features: evidence from the BRIDGE-II-Mix study. Bipolar Disord 19 (2017), 458–464.
57. Bora, E, Yucel, M, Fornito, A, Berk, M, Pantelis, C, Major psychoses with mixed psychotic and mood symptoms: are mixed psychoses associated with different neurobiological markers?. Acta Psychiatr Scand 118 (2008), 172–187.
58. Johansson, V, Kuja-Halkola, R, Cannon, TD, Hultman, CM, Hedman, AM, A population-based heritability estimate of bipolar disorder—in a Swedish twin sample. Psychiatry Res 278 (2019), 180–187.
59. Fabbri, C, The role of genetics in bipolar disorder. Curr Top Behav Neurosci, 2020 published online August 7. https://doi.org/10.1007/7854_2020_153.
60. Barnett, JH, Smoller, JW, The genetics of bipolar disorder. Neuroscience 164 (2009), 331–343.
61. Stahl, EA, Breen, G, Forstner, AJ, et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat Genet 51 (2019), 793–803.
62. Chen, DT, Jiang, X, Akula, N, et al. Genome-wide association study meta-analysis of European and Asian-ancestry samples identifies three novel loci associated with bipolar disorder. Mol Psychiatry 18 (2013), 195–205.
63. Smeland, OB, et al. Genome-wide analysis reveals extensive genetic overlap between schizophrenia, bipolar disorder, and intelligence. Mol Psychiatry 25 (2020), 844–853.
64. Wang, M, Zhang, L, Gage, FH, Modeling neuropsychiatric disorders using human induced pluripotent stem cells. Protein Cell 11 (2020), 45–59.
65. Andreazza, AC, Duong, A, Young, LT, Bipolar disorder as a mitochondrial disease. Biol Psychiatry 83 (2018), 720–721.
66. Berk, M, Kapczinski, F, Andreazza, AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 35 (2011), 804–817.
67. Brown, NC, Andreazza, AC, Young, LT, An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res 218 (2014), 61–68.
68. Goldstein, BI, Kemp, DE, Soczynska, JK, McIntyre, RS, Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 70 (2009), 1078–1090.
69. Rosenblat, JD, Cha, DS, Mansur, RB, McIntyre, RS, Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 53 (2014), 23–34.
70. Dargél, AA, Godin, O, Kapczinski, F, Kupfer, DJ, Leboyer, M, C-reactive protein alterations in bipolar disorder: a meta-analysis. J Clin Psychiatry 76 (2015), 142–150.
71. Rowland, T, Perry, BI, Upthegrove, R, et al. Neurotrophins, cytokines, oxidative stress mediators and mood state in bipolar disorder: systematic review and meta-analyses. Br J Psychiatry 213 (2018), 514–525.
72. Hamdani, N, Bengoufa, D, Godin, O, et al. Immunoglobulin sub-class distribution in bipolar disorder and schizophrenia: potential relationship with latent Toxoplasma gondii infection. BMC Psychiatry, 18, 2018, 239.
73. Hamdani, N, Daban-Huard, C, Godin, O, et al. Effects of cumulative Herpesviridae and Toxoplasma gondii infections on cognitive function in healthy, bipolar, and schizophrenia subjects. J Clin Psychiatry 78 (2017), e18–e27.
74. Frye, MA, Coombes, BJ, McElroy, SL, et al. Association of Cytomegalovirus and Toxoplasma gondii antibody titers with bipolar disorder. JAMA Psychiatry 76 (2019), 1285–1293.
75. Husain, MI, Chaudhry, IB, Khoso, AB, et al. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. Lancet Psychiatry 7 (2020), 515–527.
76. McIntyre, RS, Danilewitz, M, Liauw, SS, et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord 126 (2010), 366–387.
77. Vancampfort, D, Stubbs, B, Mitchell, AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 14 (2015), 339–347.
78. McIntyre, RS, Rong, C, Mansur, RB, Brietzke, E, Does obesity and diabetes mellitus metastasize to the brain? “Metaboptosis” and implications for drug discovery and development. CNS Spectr 24 (2019), 467–469.
79. Hajek, T, Calkin, C, Blagdon, R, Slaney, C, Alda, M, Type 2 diabetes mellitus: a potentially modifiable risk factor for neurochemical brain changes in bipolar disorders. Biol Psychiatry 77 (2015), 295–303.
80. Hajek, T, Calkin, C, Blagdon, R, Slaney, C, Uher, R, Alda, M, Insulin resistance, diabetes mellitus, and brain structure in bipolar disorders. Neuropsychopharmacology 39 (2014), 2910–2918.
81. da Silva, EG, Pfaffenseller, B, Walz, J, et al. Peripheral insulin-like growth factor 1 in bipolar disorder. Psychiatry Res 250 (2017), 30–34.
82. Milanesi, E, Zanardini, R, Rosso, G, et al. Insulin-like growth factor binding protein 2 in bipolar disorder: an expression study in peripheral tissues. World J Biol Psychiatry 19 (2018), 610–618.
83. Alageel, A, Tomasi, J, Tersigni, C, et al. Evidence supporting a mechanistic role of sirtuins in mood and metabolic disorders. Prog Neuropsychopharmacol Biol Psychiatry 86 (2018), 95–101.
84. Pinto, JV, Passos, IC, Gomes, F, et al. Peripheral biomarker signatures of bipolar disorder and schizophrenia: a machine learning approach. Schizophr Res 188 (2017), 182–184.
85. Berk, M, Post, R, Ratheesh, A, et al. Staging in bipolar disorder: from theoretical framework to clinical utility. World Psychiatry 16 (2017), 236–244.
86. Miklowitz, DJ, Scott, J, Psychosocial treatments for bipolar disorder: cost-effectiveness, mediating mechanisms, and future directions. Bipolar Disord 11:suppl 2 (2009), 110–122.
87. Berk, M, Brnabic, A, Dodd, S, et al. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disord 13 (2011), 87–98.
88. Tremain, H, Fletcher, K, Scott, J, McEnery, C, Berk, M, Murray, G, Does stage of illness influence recovery-focused outcomes after psychological treatment in bipolar disorder? A systematic review protocol. Syst Rev, 8, 2019, 125.
89. Kessing, LV, Vradi, E, Andersen, PK, Starting lithium prophylaxis early v. late in bipolar disorder. Br J Psychiatry 205 (2014), 214–220.
90. Grande, I, Berk, M, Birmaher, B, Vieta, E, Bipolar disorder. Lancet 387 (2016), 1561–1572.
91. Valli, I, Fabbri, C, Young, AH, Uncovering neurodevelopmental features in bipolar affective disorder. Br J Psychiatry 215 (2019), 383–385.
92. Garno, JL, Goldberg, JF, Ramirez, PM, Ritzler, BA, Impact of childhood abuse on the clinical course of bipolar disorder. Br J Psychiatry 186 (2005), 121–125.
93. Post, RM, Altshuler, LL, Kupka, R, et al. Age of onset of bipolar disorder: combined effect of childhood adversity and familial loading of psychiatric disorders. J Psychiatr Res 81 (2016), 63–70.
94. Post, RM, Altshuler, LL, Kupka, R, et al. Verbal abuse, like physical and sexual abuse, in childhood is associated with an earlier onset and more difficult course of bipolar disorder. Bipolar Disord 17 (2015), 323–330.
95. Leclerc, E, Mansur, RB, Grassi-Oliveira, R, et al. The differential association between history of childhood sexual abuse and body mass index in early and late stages of bipolar disorder. J Affect Disord 227 (2018), 214–218.
96. McIntyre, RS, Soczynska, JK, Liauw, SS, et al. The association between childhood adversity and components of metabolic syndrome in adults with mood disorders: results from the international mood disorders collaborative project. Int J Psychiatry Med 43 (2012), 165–177.
97. Al-Haddad, BJS, Oler, E, Armistead, B, et al. The fetal origins of mental illness. Am J Obstet Gynecol 221 (2019), 549–562.
98. Goodwin, FK, Jamison, KR, Manic-depressive illness. Bipolar disorders and recurrent depression. 2007, Oxford University Press, New York, NY.
99. Gignac, A, McGirr, A, Lam, RW, Yatham, LN, Recovery and recurrence following a first episode of mania: a systematic review and meta-analysis of prospectively characterized cohorts. J Clin Psychiatry 76 (2015), 1241–1248.
100. Kessing, LV, Andersen, PK, Vinberg, M, Risk of recurrence after a single manic or mixed episode—a systematic review and meta-analysis. Bipolar Disord 20 (2018), 9–17.
101. Tohen, M, Hennen, J, Zarate, CM Jr, et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry 157 (2000), 220–228.
102. Kessing, LV, Hansen, HV, Hvenegaard, A, et al. Treatment in a specialised out-patient mood disorder clinic v. standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial. Br J Psychiatry 202 (2013), 212–219.
103. Martin, JL, Lowrie, R, McConnachie, A, et al. Physical health indicators in major mental illness: data from the Quality and Outcome Framework in the UK. Lancet, 385(suppl 1), 2015, S61 (abstr).
104. Daivadanam, M, Ingram, M, Sidney Annerstedt, K, et al. The role of context in implementation research for non-communicable diseases: answering the “how-to” dilemma. PLoS One, 14, 2019, e0214454.
105. National Institutes of Health. Implementation science news, resources and funding for global health researchers. https://www.fic.nih.gov/researchtopics/pages/implementationscience.aspx. (Accessed 25 June 2020)
106. Hurst, JR, Dickhaus, J, Maulik, PK, et al. Global Alliance for Chronic Disease researchers' statement on multimorbidity. Lancet Glob Health 6 (2018), e1270–e1271.
107. Vancampfort, D, Firth, J, Schuch, FB, et al. Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. World Psychiatry 16 (2017), 308–315.
108. Li, X-H, An, FR, Ungvari, GS, et al. Prevalence of smoking in patients with bipolar disorder, major depressive disorder and schizophrenia and their relationships with quality of life. Sci Rep, 7, 2017, 8430.
109. Subramaniapillai, M, Arbour-Nicitopoulos, K, Duncan, M, et al. Physical activity preferences of individuals diagnosed with schizophrenia or bipolar disorder. BMC Res Notes, 9, 2016, 340.
110. Soo, SA, Zhang, ZW, Khong, SJ, et al. Randomized controlled trials of psychoeducation modalities in the management of bipolar disorder: a systematic review. J Clin Psychiatry, 79, 2018, 17r11750.
111. Rosenblat, JD, Simon, GE, Sachs, GS, et al. Frequency of use and perceived helpfulness of wellness strategies for bipolar and unipolar depression. Ann Clin Psychiatry 30 (2018), 296–304.
112. Rosenblat, JD, Simon, GE, Sachs, GS, et al. Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression. J Affect Disord 243 (2019), 116–120.
113. Fountoulakis, KN, Grunze, H, Vieta, E, et al. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines. Int J Neuropsychopharmacol 20 (2017), 180–195.
114. Yatham, LN, Kennedy, SH, Parikh, SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 20 (2018), 97–170.
115. Goodwin, GM, Haddad, PM, Ferrier, IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 30 (2016), 495–553.
116. National Collaborating Centre for Mental Health (UK). Bipolar disorder: the NICE guideline on the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. 2018, The British Psychological Society and The Royal College of Psychiatrists, London.
117. Grunze, H, Vieta, E, Goodwin, GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long-term treatment of mixed states in bipolar disorder. World J Biol Psychiatry 19 (2018), 2–58.
118. Ostacher, MJ, Tandon, R, Suppes, T, Florida best practice psychotherapeutic medication guidelines for adults with bipolar disorder: a novel, practical, patient-centered guide for clinicians. J Clin Psychiatry 77 (2016), 920–926.
119. Malhi, GS, Outhred, T, Morris, G, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: bipolar disorder summary. Med J Aust 208 (2018), 219–225.
120. Stahl, SM, Morrissette, DA, Faedda, G, et al. Guidelines for the recognition and management of mixed depression. CNS Spectr 22 (2017), 203–219.
121. McIntyre, RS, Suppes, T, Tandon, R, Ostacher, M, Florida best practice psychotherapeutic medication guidelines for adults with major depressive disorder. J Clin Psychiatry 78 (2017), 703–713.
122. Post, RM, Yatham, LN, Vieta, E, Berk, M, Nierenberg, AA, Beyond evidence-based treatment of bipolar disorder: rational pragmatic approaches to management. Bipolar Disord 21 (2019), 650–659.
123. Kessing, LV, Vradi, E, Andersen, PK, Nationwide and population-based prescription patterns in bipolar disorder. Bipolar Disord 18 (2016), 174–182.
124. Golden, JC, Goethe, JW, Woolley, SB, Complex psychotropic polypharmacy in bipolar disorder across varying mood polarities: a prospective cohort study of 2712 inpatients. J Affect Disord 221 (2017), 6–10.
125. Faurholt-Jepsen, M, Frost, M, Busk, J, et al. Is smartphone-based mood instability associated with stress, quality of life, and functioning in bipolar disorder?. Bipolar Disord 21 (2019), 611–620.
126. Nierenberg, AA, Rakhilin, M, Deckersbach, T, Objective smartphone data as a potential diagnostic marker of bipolar disorder. Aust N Z J Psychiatry 53 (2019), 171–172.
127. Faurholt-Jepsen, M, Frost, M, Christensen, EM, Bardram, JE, Vinberg, M, Kessing, LV, The association between mixed symptoms, irritability and functioning measured using smartphones in bipolar disorder. Acta Psychiatr Scand 139 (2019), 443–453.
128. Cipriani, A, Barbui, C, Salanti, G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 378 (2011), 1306–1315.
129. Yildiz, A, Nikodem, M, Vieta, E, Correll, CU, Baldessarini, RJ, A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med 45 (2015), 299–317.
130. Demyttenaere, K, Detraux, J, Racagni, G, Vansteelandt, K, Medication-induced akathisia with newly approved antipsychotics in patients with a severe mental illness: a systematic review and meta-analysis. CNS Drugs 33 (2019), 549–566.
131. Carbon, M, Kane, JM, Leucht, S, Correll, CU, Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry 17 (2018), 330–340.
132. Hui, TP, Kandola, A, Shen, L, et al. A systematic review and meta-analysis of clinical predictors of lithium response in bipolar disorder. Acta Psychiatr Scand 140 (2019), 94–115.
133. Chen, T-Y, Kamali, M, Chu, CS, et al. Divalproex and its effect on suicide risk in bipolar disorder: a systematic review and meta-analysis of multinational observational studies. J Affect Disord 245 (2019), 812–818.
134. Hampel, H, Lista, S, Mango, D, et al. Lithium as a treatment for Alzheimer's disease: the systems pharmacology perspective. J Alzheimers Dis 69 (2019), 615–629.
135. Kessing, LV, Forman, JL, Andersen, PK, Does lithium protect against dementia?. Bipolar Disord 12 (2010), 87–94.
136. Kessing, LV, Gerds, TA, Feldt-Rasmussen, B, Andersen, PK, Licht, RW, Use of lithium and anticonvulsants and the rate of chronic kidney disease: a nationwide population-based study. JAMA Psychiatry 72 (2015), 1182–1191.
137. Patel, N, Viguera, AC, Baldessarini, RJ, Mood-stabilizing anticonvulsants, spina bifida, and folate supplementation: commentary. J Clin Psychopharmacol 38 (2018), 7–10.
138. Chouchi, M, Kaabachi, W, Tizaoui, K, Daghfous, R, Aidli, SE, Hila, L, The HLA-B*15:02 polymorphism and Tegretol-induced serious cutaneous reactions in epilepsy: an updated systematic review and meta-analysis. Rev Neurol (Paris) 174 (2018), 278–291.
139. Perugi, G, Medda, P, Barbuti, M, Novi, M, Tripodi, B, The role of electroconvulsive therapy in the treatment of severe bipolar mixed state. Psychiatr Clin North Am 43 (2020), 187–197.
140. Manchia, M, Rybakowski, JK, Sani, G, et al. Lithium and bipolar depression. Bipolar Disord 21 (2019), 458–459.
141. Kelly, T, Lithium and the Woozle effect. Bipolar Disord 21 (2019), 302–308.
142. Fornaro, M, Anastasia, A, Novello, S, et al. Incidence, prevalence and clinical correlates of antidepressant-emergent mania in bipolar depression: a systematic review and meta-analysis. Bipolar Disord 20 (2018), 195–227.
143. Pacchiarotti, I, Bond, DJ, Baldessarini, RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 170 (2013), 1249–1262.
144. Sidor, MM, MacQueen, GM, Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry 72 (2011), 156–167.
145. Altshuler, LL, Sugar, CA, McElroy, SL, et al. Switch rates during acute treatment for bipolar II depression with lithium, sertraline, or the two combined: a randomized double-blind comparison. Am J Psychiatry 174 (2017), 266–276.
146. Bahji, A, Hawken, ER, Sepehry, AA, Cabrera, CA, Vazquez, G, ECT beyond unipolar major depression: systematic review and meta-analysis of electroconvulsive therapy in bipolar depression. Acta Psychiatr Scand, 20, 2018, 539.
147. Rachid, F, Repetitive transcranial magnetic stimulation and treatment-emergent mania and hypomania: a review of the literature. J Psychiatr Pract 23 (2017), 150–159.
148. Myczkowski, ML, Fernandes, A, Moreno, M, et al. Cognitive outcomes of TMS treatment in bipolar depression: safety data from a randomized controlled trial. J Affect Disord 235 (2018), 20–26.
149. Yang, L-L, Zhao, D, Kong, LL, et al. High-frequency repetitive transcranial magnetic stimulation (rTMS) improves neurocognitive function in bipolar disorder. J Affect Disord 246 (2019), 851–856.
150. Hidalgo-Mazzei, D, Berk, M, Cipriani, A, et al. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition. Br J Psychiatry 214 (2019), 27–35.
151. Lindström, L, Lindström, E, Nilsson, M, Höistad, M, Maintenance therapy with second generation antipsychotics for bipolar disorder—a systematic review and meta-analysis. J Affect Disord 213 (2017), 138–150.
152. Miura, T, Noma, H, Furukawa, TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry 1 (2014), 351–359.
153. Ketter, TA, Calabrese, JR, Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry 63 (2002), 146–151.
154. Lähteenvuo, M, Tanskanen, A, Taipale, H, et al. Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder. JAMA Psychiatry 75 (2018), 347–355.
155. Matsubara, T, Matsuo, K, Harada, K, et al. Distinct and shared endophenotypes of neural substrates in bipolar and major depressive disorders. PLoS One, 11, 2016, e0168493.
156. Miskowiak, KW, Burdick, KE, Martinez-Aran, A, et al. Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force. Bipolar Disord 19 (2017), 614–626.
157. Kessing, LV, Miskowiak, K, Does cognitive dysfunction in bipolar disorder qualify as a diagnostic intermediate phenotype?—a perspective paper. Front Psychiatry, 9, 2018, 490.
158. Burdick, KE, Millett, CE, Bonnín, CDM, et al. The International Consortium Investigating Neurocognition in Bipolar Disorder (ICONIC-BD). Bipolar Disord 21 (2019), 6–10.
159. Bora, E, McIntyre, RS, Ozerdem, A, Neurococognitive and neuroimaging correlates of obesity and components of metabolic syndrome in bipolar disorder: a systematic review. Psychol Med 49 (2019), 738–749.
160. Bond, DJ, Torres, IJ, Lee, SS, et al. Lower cognitive functioning as a predictor of weight gain in bipolar disorder: a 12-month study. Acta Psychiatr Scand 135 (2017), 239–249.
161. McIntyre, RS, Is obesity changing the phenotype of bipolar disorder from predominately euphoric toward mixed presentations?. Bipolar Disord 20 (2018), 685–686.
162. Mason, L, O'Sullivan, N, Montaldi, D, Bentall, RP, El-Deredy, W, Decision-making and trait impulsivity in bipolar disorder are associated with reduced prefrontal regulation of striatal reward valuation. Brain 137 (2014), 2346–2355.
163. Kirschner, M, et al. Shared and dissociable features of apathy and reward system dysfunction in bipolar I disorder and schizophrenia. Psychol Med 50 (2020), 935–947.
164. Dutra, SJ, Man, V, Kober, H, Cunningham, WA, Gruber, J, Disrupted cortico-limbic connectivity during reward processing in remitted bipolar I disorder. Bipolar Disord 19 (2017), 661–675.
165. Miskowiak, KW, Carvalho, AF, Vieta, E, Kessing, LV, Cognitive enhancement treatments for bipolar disorder: a systematic review and methodological recommendations. Eur Neuropsychopharmacol 26 (2016), 1541–1561.
166. Viktorin, A, Rydén, E, Thase, ME, et al. The risk of treatment-emergent mania with methylphenidate in bipolar disorder. Am J Psychiatry 174 (2017), 341–348.
167. Hollis, C, Chen, Q, Chang, Z, et al. Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study. Lancet Psychiatry 6 (2019), 651–658.
168. Łojko, D, Stelmach-Mardas, M, Suwalska, A, Diet quality and eating patterns in euthymic bipolar patients. Eur Rev Med Pharmacol Sci 23 (2019), 1221–1238.
169. Subramaniapillai, M, Mansur, RB, Zuckerman, H, et al. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine. Compr Psychiatry, 94, 2019, 152113.
170. McIntyre, RS, Lophaven, S, Olsen, CK, A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 17 (2014), 1557–1567.
171. Henter, ID, de Sousa, RT, Zarate, CA Jr, Glutamatergic modulators in depression. Harv Rev Psychiatry 26 (2018), 307–319.
172. Mansur, RB, Zugman, A, Ahmed, J, et al. Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders. Eur Neuropsychopharmacol 27 (2017), 1153–1162.
173. Rutkofsky, IH, Khan, AS, Sahito, S, Kumar, V, The psychoneuroimmunological role of omega-3 polyunsaturated fatty acids in major depressive disorder and bipolar disorder. Adv Mind Body Med 31 (2017), 8–16.
174. Saunders, EFH, Ramsden, CE, Sherazy, MS, Gelenberg, AJ, Davis, JM, Rapoport, SI, Omega-3 and omega-6 polyunsaturated fatty acids in bipolar disorder: a review of biomarker and treatment studies. J Clin Psychiatry 77 (2016), e1301–e1308.
175. Coello, K, Hansen, TH, Sørensen, N, et al. Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. Brain Behav Immun 75 (2019), 112–118.
176. McIntyre, RS, Subramaniapillai, M, Shekotikhina, M, et al. Characterizing the gut microbiota in adults with bipolar disorder: a pilot study. Nutr Neurosci, 2019 published online May 28. https://doi.org/10.1080/1028415X.2019.1612555.
177. Husain, MI, Chaudhry, IB, Husain, N, et al. Minocycline as an adjunct for treatment-resistant depressive symptoms: a pilot randomised placebo-controlled trial. J Psychopharmacol 31 (2017), 1166–1175.
178. Rosenblat, JD, McIntyre, RS, Efficacy and tolerability of minocycline for depression: a systematic review and meta-analysis of clinical trials. J Affect Disord 227 (2018), 219–225.
179. McIntyre, RS, Lipsitz, O, Rodrigues, NB, The effectiveness of ketamine on anxiety, irritability, and agitation: implications for treating mixed features in adults with major depressive or bipolar disorder. Bipolar Disord, 2020 published online May 13. https://doi.org/10.1111/bdi.12941.
180. Rybakowski, JK, Permoda-Osip, A, Bartkowska-Sniatkowska, A, Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression. Int J Psychiatry Clin Pract 21 (2017), 99–103.
181. Zarate, CA Jr, Brutsche, NE, Ibrahim, L, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71 (2012), 939–946.
182. Lee, Y, Syeda, K, Maruschak, NA, et al. A new perspective on the anti-suicide effects with ketamine treatment: a procognitive effect. J Clin Psychopharmacol 36 (2016), 50–56.
183. Dakwar, E, Nunes, EV, Hart, CL, et al. A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial. Am J Psychiatry 176 (2019), 923–930.
184. Zheng, W, Zhang, QE, Cai, DB, et al. N-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials. Acta Psychiatr Scand 137 (2018), 391–400.
185. McIntyre, RS, Subramaniapillai, M, Lee, Y, et al. Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar i/ii depression: a randomized clinical trial. JAMA Psychiatry, 76, 2019, 783.
186. Mansur, RB, Ahmed, J, Cha, DS, et al. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study. J Affect Disord 207 (2017), 114–120.
187. Brown, ES, Park, J, Marx, CE, et al. A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression. Neuropsychopharmacology 39 (2014), 2867–2873.
188. Meltzer-Brody, S, Colquhoun, H, Riesenberg, R, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet 392 (2018), 1058–1070.
189. Gunduz-Bruce, H, Silber, C, Kaul, I, et al. Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med 381 (2019), 903–911.
190. Youssef, NA, Bradford, DW, Kilts, JD, et al. Exploratory investigation of biomarker candidates for suicide in schizophrenia and bipolar disorder. Crisis 36 (2015), 46–54.
191. Grigolon, RB, Trevizol, AP, Cerqueira, RO, et al. Hypersomnia and bipolar disorder: a systematic review and meta-analysis of proportion. J Affect Disord 246 (2019), 659–666.
192. Moreira, J, Geoffroy, PA, Lithium and bipolar disorder: impacts from molecular to behavioural circadian rhythms. Chronobiol Int 33 (2016), 351–373.
193. Yatham, LN, Vieta, E, Goodwin, GM, et al. Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial. Br J Psychiatry 208 (2016), 78–86.
194. Prieto, DI, Zehgeer, AA, Connor, DF, Use of suvorexant for sleep regulation in an adolescent with early-onset bipolar disorder. J Child Adolesc Psychopharmacol, 29, 2019, 395.
195. Shariq, AS, Rosenblat, JD, Alageel, A, et al. Evaluating the role of orexins in the pathophysiology and treatment of depression: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 92 (2019), 1–7.
196. Geddes, JR, Gardiner, A, Rendell, J, et al. Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial. Lancet Psychiatry 3 (2016), 31–39.
197. Mischoulon, D, Zajecka, J, Freeman, MP, Fava, M, Does folic acid interfere with lamotrigine?. Lancet Psychiatry 3 (2016), 704–705.